IMNN-001 combined with standard neoadjuvant/adjuvant chemotherapy and bevacizumab - (MRD)

July 21, 2026: IMUNON, Inc. (NASDAQ: IMNN) reported new positive preliminary data from its ongoing Phase 2 minimal residual disease (MRD) translational trial (NCT05739981) of IMNN-001 plus standard neoadjuvant/adjuvant chemotherapy and bevacizumab in women with newly diagnosed advanced ovarian cancer, conducted with Break Through Cancer/UT MD Anderson.

At the primary assessment point (second-look laparoscopy), nine patients per arm had reached evaluation. Versus control, IMNN-001 showed a lower MRD-positive rate (44% vs. 67%), higher circulating tumor DNA (ctDNA) clearance (87.5% vs. 62.5%), and a numerically higher “no evidence of disease” rate following frontline therapy (100% vs. 56%). Safety/tolerability remained favorable, with no cytokine release syndrome, systemic toxicities, or serious immune-related adverse events reported to date in this study.

The company said these findings build on its completed Phase 2 OVATION 2 study, which reported improved median overall survival vs chemotherapy alone (45.1 vs. 30.4 months), including in patients receiving PARP inhibitor maintenance (65.6 vs. 41.4 months). IMNN-001 is also being evaluated in the ongoing pivotal Phase 3 OVATION 3 trial, which is recruiting across U.S. sites.